Concepts (93)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Kidney Transplantation | 9 | 2019 | 120 | 0.730 |
Why?
|
| Renal Dialysis | 5 | 2022 | 108 | 0.730 |
Why?
|
| Arteriovenous Shunt, Surgical | 4 | 2022 | 17 | 0.630 |
Why?
|
| Immunosuppressive Agents | 7 | 2019 | 124 | 0.590 |
Why?
|
| Catheter Obstruction | 1 | 2013 | 2 | 0.440 |
Why?
|
| Angioplasty, Balloon | 1 | 2013 | 13 | 0.440 |
Why?
|
| Blood Vessel Prosthesis Implantation | 1 | 2013 | 17 | 0.440 |
Why?
|
| Blood Vessel Prosthesis | 1 | 2013 | 10 | 0.430 |
Why?
|
| Catheterization, Central Venous | 1 | 2013 | 34 | 0.420 |
Why?
|
| Stents | 1 | 2013 | 76 | 0.410 |
Why?
|
| Graft Occlusion, Vascular | 3 | 2022 | 18 | 0.300 |
Why?
|
| Liver Transplantation | 2 | 2014 | 65 | 0.300 |
Why?
|
| Graft Survival | 6 | 2019 | 90 | 0.290 |
Why?
|
| Mycophenolic Acid | 5 | 2019 | 9 | 0.280 |
Why?
|
| Graft Rejection | 4 | 2019 | 63 | 0.280 |
Why?
|
| Tacrolimus | 5 | 2019 | 15 | 0.270 |
Why?
|
| Vascular Patency | 4 | 2022 | 12 | 0.270 |
Why?
|
| Kidney Failure, Chronic | 2 | 2019 | 151 | 0.250 |
Why?
|
| Carrier Proteins | 2 | 2016 | 79 | 0.240 |
Why?
|
| Upper Extremity | 2 | 2016 | 63 | 0.240 |
Why?
|
| Aneurysm | 1 | 2022 | 10 | 0.200 |
Why?
|
| Isoxazoles | 1 | 2002 | 5 | 0.200 |
Why?
|
| Arteriovenous Fistula | 1 | 2022 | 11 | 0.200 |
Why?
|
| Treatment Outcome | 9 | 2022 | 3390 | 0.190 |
Why?
|
| Surgical Instruments | 1 | 2020 | 21 | 0.180 |
Why?
|
| Cyclosporine | 3 | 2007 | 11 | 0.180 |
Why?
|
| Sirolimus | 3 | 2005 | 19 | 0.180 |
Why?
|
| Health Care Costs | 1 | 2020 | 66 | 0.170 |
Why?
|
| Time Factors | 8 | 2022 | 1382 | 0.170 |
Why?
|
| Pancreatic Elastase | 2 | 2016 | 5 | 0.170 |
Why?
|
| Suture Techniques | 1 | 2020 | 150 | 0.170 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2019 | 87 | 0.160 |
Why?
|
| Recombinant Fusion Proteins | 2 | 2010 | 25 | 0.160 |
Why?
|
| Brachial Artery | 1 | 2016 | 4 | 0.140 |
Why?
|
| Radial Artery | 1 | 2016 | 7 | 0.140 |
Why?
|
| Postoperative Complications | 2 | 2020 | 868 | 0.140 |
Why?
|
| Retrospective Studies | 4 | 2022 | 3366 | 0.130 |
Why?
|
| Male | 12 | 2020 | 14123 | 0.120 |
Why?
|
| Female | 12 | 2020 | 14516 | 0.120 |
Why?
|
| Creatinine | 5 | 2010 | 45 | 0.120 |
Why?
|
| Liver Cirrhosis | 1 | 2014 | 42 | 0.120 |
Why?
|
| Humans | 14 | 2022 | 26257 | 0.110 |
Why?
|
| Middle Aged | 10 | 2020 | 8599 | 0.110 |
Why?
|
| Renal Insufficiency, Chronic | 1 | 2014 | 89 | 0.100 |
Why?
|
| Risk Factors | 5 | 2022 | 2265 | 0.100 |
Why?
|
| Adult | 9 | 2020 | 7447 | 0.090 |
Why?
|
| Prosthesis Design | 1 | 2013 | 482 | 0.090 |
Why?
|
| Membrane Glycoproteins | 1 | 2010 | 67 | 0.090 |
Why?
|
| Double-Blind Method | 3 | 2016 | 400 | 0.080 |
Why?
|
| Drug Therapy, Combination | 2 | 2005 | 170 | 0.070 |
Why?
|
| Aged | 7 | 2020 | 8763 | 0.070 |
Why?
|
| Calcineurin Inhibitors | 2 | 2005 | 16 | 0.070 |
Why?
|
| Antibodies, Monoclonal | 1 | 2007 | 192 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 2 | 2016 | 162 | 0.060 |
Why?
|
| Renal Insufficiency | 1 | 2005 | 13 | 0.060 |
Why?
|
| Survival Analysis | 3 | 2014 | 235 | 0.060 |
Why?
|
| Prospective Studies | 4 | 2016 | 1668 | 0.060 |
Why?
|
| Prognosis | 2 | 2019 | 758 | 0.050 |
Why?
|
| Prednisone | 1 | 2002 | 61 | 0.050 |
Why?
|
| Cost Savings | 1 | 2020 | 30 | 0.050 |
Why?
|
| Anemia | 1 | 2002 | 93 | 0.050 |
Why?
|
| Cost-Benefit Analysis | 1 | 2020 | 126 | 0.040 |
Why?
|
| Equivalence Trials as Topic | 1 | 2019 | 2 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2019 | 21 | 0.040 |
Why?
|
| United States | 2 | 2016 | 1989 | 0.040 |
Why?
|
| Follow-Up Studies | 2 | 2019 | 1738 | 0.040 |
Why?
|
| Transplantation, Homologous | 2 | 2010 | 287 | 0.030 |
Why?
|
| Waiting Lists | 1 | 2014 | 14 | 0.030 |
Why?
|
| Administration, Cutaneous | 1 | 2014 | 4 | 0.030 |
Why?
|
| Constriction, Pathologic | 1 | 2014 | 26 | 0.030 |
Why?
|
| Recombinant Proteins | 1 | 2014 | 200 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2014 | 315 | 0.030 |
Why?
|
| Databases, Factual | 1 | 2014 | 333 | 0.030 |
Why?
|
| Kidney | 2 | 2005 | 156 | 0.030 |
Why?
|
| Ultrasonography | 1 | 2014 | 222 | 0.030 |
Why?
|
| Kidney Function Tests | 1 | 2010 | 22 | 0.020 |
Why?
|
| Reperfusion Injury | 1 | 2010 | 6 | 0.020 |
Why?
|
| Tissue Donors | 1 | 2010 | 72 | 0.020 |
Why?
|
| Tablets, Enteric-Coated | 1 | 2007 | 1 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2007 | 57 | 0.020 |
Why?
|
| Monitoring, Physiologic | 1 | 2007 | 73 | 0.020 |
Why?
|
| Postoperative Period | 1 | 2007 | 312 | 0.020 |
Why?
|
| Glomerular Filtration Rate | 1 | 2005 | 51 | 0.020 |
Why?
|
| Biopsy | 1 | 2005 | 200 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2010 | 1838 | 0.020 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2005 | 99 | 0.010 |
Why?
|
| Pilot Projects | 1 | 2005 | 378 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2003 | 14 | 0.010 |
Why?
|
| Acute Disease | 1 | 2003 | 192 | 0.010 |
Why?
|
| Cross-Over Studies | 1 | 2002 | 59 | 0.010 |
Why?
|
| Hypertension | 1 | 2003 | 222 | 0.010 |
Why?
|
| Incidence | 1 | 2003 | 716 | 0.010 |
Why?
|
| Cardiovascular Diseases | 1 | 2003 | 333 | 0.010 |
Why?
|